Summit Therapeutics Inc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2022
May 11, 2022 16:30 ET
|
Summit Therapeutics Inc.
Cambridge, MA, May 11, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational...
Taconic Biosciences and Biomodels Establish Microbiome Initiative
April 26, 2022 09:00 ET
|
Taconic Biosciences
RENSSELAER, N.Y., April 26, 2022 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, and Biomodels, a provider of contract research services...
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2021
March 17, 2022 16:14 ET
|
Summit Therapeutics Inc.
Cambridge, MA, March 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its...
Summit Therapeutics Today Presents Its Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference
January 10, 2022 08:00 ET
|
Summit Therapeutics Inc.
Cambridge, Massachusetts, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) reminds interested stakeholders that it will today present the...
Summit Therapeutics to Present Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference
January 05, 2022 07:30 ET
|
Summit Therapeutics Inc.
Cambridge, Massachusetts, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that it will present the Company’s vision...
Summit Therapeutics Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection
December 20, 2021 08:30 ET
|
Summit Therapeutics Inc.
Cambridge, MA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced topline results for the Phase III Ri-CoDIFy study evaluating its...
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2021
November 15, 2021 08:30 ET
|
Summit Therapeutics Inc.
Cambridge, Massachusetts, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on...
The Biocodex Microbiota Foundation calls for Canadian proposals to study the microbiome’s role in health and diseases
July 28, 2021 10:39 ET
|
Biocodex Canada
MONTREAL, July 28, 2021 (GLOBE NEWSWIRE) -- The Biocodex Microbiota Foundation, an organization founded by Biocodex and dedicated to inspiring scientific projects that explore the microbiome, is...
Biocodex Microbiota Foundation lance un appel à propositions au Canada pour financer une étude sur le rôle joué par le microbiome dans la santé et les maladies
July 28, 2021 10:39 ET
|
Biocodex Canada
MONTRÉAL, 28 juill. 2021 (GLOBE NEWSWIRE) -- Biocodex Microbiota Foundation, organisme fondé par Biocodex et dédié à soutenir des projets scientifiques inspirants qui explorent le microbiome, lance un...
Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Rated ePoster
July 01, 2021 08:00 ET
|
Summit Therapeutics Inc.
Cambridge, MA, July 01, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (the “Company”) today announced that members of our scientific team will present breakthrough research...